Dermata Therapeutics, Inc. (DRMA) company profile
Close on Nov 13, 2026Market cap $2.50MP/E –Yield –
About Dermata Therapeutics
Pharmaceutical Preparations, SIC 2834
Dermata Therapeutics, Inc. is a scientific skincare company focused on developing and commercializing treatments for common and underserved dermatological conditions, such as acne. The company is shifting its strategic focus from prescription pharmaceuticals toward science-backed, direct-to-consumer and professional business-to-business skincare lines, branded as Tome. Its planned product portfolio includes foundational topical treatments and over-the-counter acne systems utilizing a purified freshwater sponge powder known as Spongilla lacustris, or Bioneedle, combined with active ingredients like salicylic acid. Beyond topical acne solutions, the company explores applications for its microstructure technology to facilitate intradermal delivery of aesthetic treatments.
The company's primary target market includes consumers seeking over-the-counter skin wellness products as well as dermatologists and aesthetic healthcare professionals. Dermata operates from its principal executive offices located in San Diego, California. The text does not report retail store locations or international business figures.
Summary of the business section of Dermata Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Dermata Therapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 3525 Del Mar Heights Rd., #322 92130
- Phone
- (858) 223-0882
- Website
- dermatarx.com
- Employees
- 9, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C, San Diego, California
Stock & identifiers
- Ticker
- DRMA
- Exchange
- Nasdaq
- IPO date
- Aug 16, 2021
- Shares outstanding
- 4M, Aug 10, 2026
- Public float
- $3.10M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Aug 1, 2025; 1-for-15 reverse, May 16, 2024; 1-for-16 reverse, Mar 14, 2023
- SEC CIK
- 1853816
- CUSIP
- 249845108
- ISIN
- US2498451085
- FIGI
- BBG011DJT0X2
- Share class FIGI
- BBG011DJT0Y1
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gerald T. Proehl | PRESIDENT, CHAIRMAN, CEO, Director | 372,615 |
| Hoose Kyri K. Van | SVP, CFO | 232,463 |
| Munera Maria E. Bedoya-Toro | SVP, Regulatory Affairs | 1,046 |
| Christopher J. Nardo | Senior VP, CDO | 27,560 |
| Kathleen D. Scott | Director | 1 |
| Mary Fisher | Director | 196,946 |
| Andrew Seth Sandler | Director | 24,184 |
| David F. Hale | Director | 81,469 |
| Steven J. Mento | Director | – |
| Wendell Wierenga | Director | 62,398 |
| Brittany Bradrick | Director | 23,443 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Total | vs. prior year |
|---|---|---|---|---|---|
| Gerald T. Proehl President and Chief Executive Officer | $280.00K | $140.00K | $52.52K | $472.52K | +2% |
| Kyri K. Van Hoose Senior Vice President, Chief Financial Officer | $346.57K | $138.63K | $23.34K | $508.54K | +9% |
| Christopher J. Nardo, Ph.D. Senior Vice President, Chief Development Officer | $366.98K | $146.79K | $23.34K | $537.11K | +9% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 16, 2021
- Offer price
- $7.00
- Securities offered
- 2,571,428
- Gross proceeds
- $18.00M
- Exchange
- Nasdaq
- First trading day
- Aug 13, 2021
- First-day close
- $5.19-25.9%
- Lock-up ends (est.)
- Feb 9, 2022
“Per Unit Total Initial public offering price $ 7.00 $ 17,999,996 Underwriting discounts and commissions (1) $ 0.56 $ 1,440,000 Proceeds to us, before expenses $ 6.44 $ 16,559,996 (1) Does not include the reimbursement of certain expenses of the underwriters.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of the date of this report, we have nine full-time employees, with four employees working in the selling, general and administrative department, two engaged in non-clinical and clinical development, two working in the chemistry, manufacturing, and controls department, and one employee working in the regulatory affairs and quality control department.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?